Primary immune thrombocytopenia (ITP) research hub
5 indexed studies · 2 currently recruiting
- ongoing, recruitingHuman Pharmacology (Phase I)- Other
Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia
This study is looking at a new medicine called HMPL-523 for adults with a blood condition called immune thrombocytopenia (ITP). It will check if the medicine is safe, how it works in the body, and if it helps people with ITP.
Norway · Spain · Germany - active not recruitingPHASE3
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
This study is looking at a new medicine called ianalumab for adults with a blood condition called ITP. We want to see if ianalumab, when given with standard treatment (steroids), can help keep platelet counts up. Half the participants will get ianalumab, and half will get a dummy medicine.
United States · Argentina · Australia - recruitingPHASE3
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
This study is testing a new medicine called efgartigimod for adults with a blood condition called primary immune thrombocytopenia (ITP). Researchers want to see if it's safe and helps increase blood platelet counts. Some people will get the study drug, others a placebo (dummy drug).
United States · Austria · Bulgaria - active not recruitingPHASE2
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
This study is looking at a new medicine called ianalumab for adults with a blood condition called ITP. We want to see how well it works, if it's safe, and how people tolerate it, especially if other treatments haven't helped enough.
United States · Argentina · Australia - recruitingPHASE3
Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia
This study looks at a new way to treat a blood problem called ITP in adults. It combines an existing drug, rituximab, with a new one, belimumab, to see if it works better than rituximab alone in boosting platelet counts.
France